**SWOG-S1614** Tenofovir Alafenamide in Preventing Liver Complications in Participants With Current or Past Hepatitis B Virus Who Are Receiving Anti-Cancer Therapy for Solid Tumors. TM: G. Facio

**Breast**

*0S-10-3* Rand Ph II Cont Diet for Breast/Prostate Ca-Tox/Efficacy. TM: G. Facio

**1B-10-3** (Re-activated 12/07/17) I-SPY 2 Brst Ca. TM: G. Facio

**1B-11-1** Bld Bio Repository. TM: G. Facio / Massopust

**NB/HOAG**

**1B-11-8** (1/22/15: DSMC suspension) In Vivo Cell Light-Scattering Spectroscopy - Breast. J Choudhury

**1B-11-15** Combined Breast MRI/Biomarker Strategies. TM: G. Facio

**1B-17-3** Combined Breast MRI/Imaging in Rad Onc. PI: Michael Reilly, MD

**1B-18-1** Phi ARX788 as single agent in Advanced Cancers with HER2Expression. TM: G. Facio

**ctsu-A221505** Ph3 Hypofractionated Post Mastectomy Radiation w/ Breast Reconstruction. TM: G. Facio

**ctsu/CALGB-A011202** Ph III Axillary LN Dissection in Pts w/+DLBCL. TM: X. Menendez/ Nguyen (HOAG)

**ctsu/NSABP-B-51/RTOG1304** Ph2/Assessing the Accuracy of Tumor Bed Biopsies. TM: G. Facio

**ctsu/ctsu-EAF151** Eflornithine+Lomustine Compared to Lomustine Alone Stellar Study. Lozada

**ctsu/EAY131** Molecular Analysis for Therapy Choice (MATCH). TM: X. Menendez, C. Kefauver

**ctsu-A031702** Study of Ipilimumab, Cabozantinib, and Deaminase Inhibitor With Oral Decitabine in Subjects With Advanced Solid Tumors. TM: X. Menendez / Andres (HOAG)

**1B-20-1** Ibrutinib + Tx/GI-GU Tumors. TMs: C. Ketchens / Andres (HOAG)

**1B-20-2** Ph1/OL/Dose Escalation MGD013 in Unresectable CNS Tumors. TM: X. Menendez / Andres (HOAG)

**1B-21-0** Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy Versus Radiotherapy Alone for Inflammatory Breast Cancer. TM: G. Facio

**SWOG-S1670** Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy Versus Radiotherapy Alone for Inflammatory Breast Cancer. TM: G. Facio

**CNS Tumors**

**6B-15-1** NovoTFF -200A fields) in Patients with High Risk Oligodendrogliomas. Leong

**6B-17-1** Efllomithione+Lomustine Compared to Lomustine Alone Stellar Study. Lozada

**6CNS-07-1** CNS & Spine Tumor Bank. Leong

**6G-15-2** Ph1/2a NEO100 in Recurrent Gr IV Glioma. Lozada

**CTSU-EAP151** -Cerebral Bld Vol as Biomarker for Early Region-6 GBM in Glioblastoma. B. Desai

**NRR-BN003** Ph3 Observation vs Irradtx in Gr II Meningioma. TM: C. Ketchens

**1B-99-9** Blood Collection in GI Cancer. TM: C. Ketchens
GI – Bile Duct
3BD-18-1 Phase 3 Study of BGJ398 (Oral Infritinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations. TM: C. Ketchens

GI – Esophagus
*3C-15-4 High Definition Single Cell Analysis in CRC. Garcia-Leiva/Lujan/Massopust/Bogardus (NB/H)

GI - Colorectal
*3C-15-10 Ph3 Arfolitixorin Vs Leuco + 5-FU, Oxali, Beva In Advanced CRC/TUM: C. Ketchens / Andres (HOAG)

3C-19-1: Ph 1b/2 Onvansertib + FOLFI R + Bevacizumab for 2nd line T/M of mCRC with Kras Mutation. TM: C. Ketchens/ X. Menendez

3C-19-3: PHI-186: Ph 2 Savolitinib in Subjects with MET Amplified mCRC TM: C. Ketchens

3C-19-4: AYA CRC. Marin/Cohen-Cutler

3C-19-5: Study of Tisitolomod in Combination With Nivolumab and Ipi lin mAb for the Treatment of Solid Tumors (ILLUMINATE-206). TM: C. Ketchens

3C-19-6: Phase 1b Safety/Tolerability/Anti-Tumor Activity of ATP128, +/- BI 754091 in Stage IV CRC. TM: C. Ketchens

3C-19-8 (SUSPENDED) Nivolumab, Nivolumab Plus Ipi lin mAb, or Investigator's Choice Chemotherapy for the Treatment of Patients With Deficient Mismatch Repair (dMMR/Microsatellite Instability High (MSI-H)/Metastatic Colorectal Cancer (mCRC) (CheckMate 8HW). TM: C. Ketchens

3C-20-2: Panitumumab, Regorafenib, or TAS-102, In Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer. TM: C. Ketchens

3C-20-3 MOUNTAINEER: Ph2 Tucatinib + Trastuzumab in HER2+ mCRC. TM: C. Ketchens

CTSU-A021502 SOC Alone or Combi w/ Atezolizumab in St 3 Colon CA and Def DNA Mismatch. TM: C. Ketchens

CTSU-A021703 Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced/ Metastatic Colorectal Cancer (SOLARIS). TM: C. Ketchens

SWOG-S0820 Ph III Eflornithine vs Sulindac vs Placebo Colon Adenomas & 2nd Prim Ca. TM: C. Ketchens / K. Massopust (NB)

SWOG-S1613 Ph2 Trast + Pert vs Cetux + Irino in mCRC with HER-2 Amplification. TM: C. Ketchens

GI - Rectal
CTSU/NRG-GI002 Ph II TNT in Rectal Cancer. TM: C. Ketchens

3G-07-3 Cell Lines/Xenografts – Adult Solid Tumors & Inflammatory bowel dz. TM: C. Ketchens

3G-17-2 (ONLY 2L COHORT OPEN) Ph1b/2 Mult Immunob in gastric or GEJ CA. TM: C. Ketchens

GI – Anus
3A-15-1 Ph 2 Nivo +/- Ipili in Refractory Met Sq Cell CA of the Anal Canal. TM: C. Ketchens


GI – Liver
3L-17-1 pl of AFPCC32T in HLA-A2+ in HCC. TM: X. Menendez

3L-17-4 5 YR Obs Study Hx & Mx of Liver CA. TM: C. Ketchens

3L-17-5 Ph2b regorafenib+ pembrolizumab in advanced HCC. TM: C. Ketchens

3L-19-1 Ph3/Rand 18 (XL184) + Atevo vs Sorafenib in Adv HCC with Prevoys Sys AntiCAX.. TM: C. Ketchens / Andres (HOAG)

GI – Gallbladder/Biliary Tract
3GB-14-1 Ph2 BGI398 in advanced or met. cholangioCA. TM: C. Ketchens

GI – Pancreas
3P-18-2 Ph 1/2 Safety/Tolerability/Pk of GP-2250 + Gem in PanC AdenoCA Progressed. TM: X. Menendez / Andres (HOAG)

3P-19-1 Ph3 Pamrevlumab Placebo+Gem+Nab-pacl as Neoadj T/M in Local Adv, Unresect PanC CATM: C. Ketchens / Andres (HOAG)

3P-19-3 Anerolum Rvatnsine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer. TM: C. Ketchens

GI Rectal
3G-18-3 Ph2ZW52 +Istli + Chemo in HER2-Expressing in GEA. TM: C. Ketchens / Andres (HOAG)

3G-19-1 Pembrolizumab, Capevidop, and Radiation Therapy in Treating Patients With Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer. TM: C. Ketchens

3G-19-2 Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Tx of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW). TM: C. Ketchens

3G-19-3 Ph2, Trastuzumab deruxtecan (DS-8201A) in HER2+ unresectable/met Gastric or GEJ Progressed on or post trastuzumab containing Reg. TM: C. Ketchens

GI – Stomach
3G-18-3 Ph2 ZW52 +Istli + Chemo in HER2-Expressing in GEA. TM: C. Ketchens / Andres (HOAG)

3G-19-1 Pembrolizumab, Capevidop, and Radiation Therapy in Treating Patients With Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer. TM: C. Ketchens

3G-19-2 Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Tx of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW). TM: C. Ketchens

3G-19-3 Ph2, Trastuzumab Deruxtecan (DS-8201A) in HER2+ unresectable/met Gastric or GEJ Progressed on or post trastuzumab containing Reg. TM: C. Ketchens

GU – Adrenals

4B-15-11 Plt of sEphB4-HAS+ Pembrozulam MK-7435. TM: C. Kefauver

4B-16-8 (SUSPENDED) PhII-147 MLN0128 patients w/ mTCC, TSC1 and/or TSC2 mutation.. TM: C. Kefauver

4B-17-5 PhII-150 Erubilin Mesylate +Atevo vs Atezo Alone in TCC. TM: C. Kefauver


4B-18-4 Neoadj gemcis/nivolumab in ms-inv bladder CA w/ selective bladder sparring. TM: C. Kefauver

4B-18-5 PhII-176 Olaparib in Met/Adv Urothelial Ca w/ DNA-Repair Defects. TM: C. Kefauver

4B-19-1 The Oxbladder Hematuria Clinical Utility Study. TM: C. Kefauver


4B-19-4 Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer (CISTO). TM: C. Kefauver

4B-19-6 Placebo-Controlled Trial of Infritinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF 302). TM: C. Kefauver

4B-20-1 Intravesical Phase 1/1b Study of STING Agonist AYA CRC. Marin/Cohen-Cutler

GU – Renal
4K-14-4 MDSC Clinical Assay/RCC. TM: C. Kefauver

4K-16-5 PII PF04518600+Axitinib or Met RCC TM: C. Kefauver

4K-18-2 Ph2 PT2977 + Cabozantinib in Patients with Advanced Clear Cell RCC Team/Kefauver

CTSU-A031501 Ph3 MK-3475 in muscle invasive Urothelial CA vs observation. TM: C. Kefauver

SWOG-S1602 Ph3 to Eval BCG Strain + T Cell Priming for BCG-Naive HGBC. TM: C. Kefauver

GU – Genitourinary
4P-11-4 CTC Assessment: Prostate. TM: C. Kefauver / O. Castellanos (Westside)

4P-12-3 SWOG-S1613 Int’l Penile Advanced Cancer Trial (InPact). TM: C. Kefauver

GU – Bladder
4P-17-3 TRITON3, Ph3 Rucaparib vs Physician’s Choice in mCRPC. TM: C. Kefauver / O. Castellanos (Westside)

GU – Prostate
4S-10-4 (PROSTATE ONLY) Ph II Controlled Diet for Breast/Prostate Ca – TM: C. Kefauver / Massopust (NB)

4P-11-4 CTC Assessment: Prostate. TM: C. Kefauver / O. Castellanos (Westside)

4P-12-3 MDSC Assay: Ca Detection/Monitoring. Karimi TM: C. Ketchens

4P-14-4 Cell-Free DNA & RNA in Blid. G. Danenberg

4P-16-2 Enzalutamide or Radium223/Prostate Cancer TM: C. Kefauver

4P-16-3 (SUSPENDED) 18F-MFAU PET/PC. B. Desai

4P-17-3 TRITON3, Ph3 Rucaparib vs Physician’s Choice in mCRPC. TM: C. Kefauver / O. Castellanos (Westside)

4P-17-4 Prostate Biomarkers for Repeat Bx. Ileana Aldana
NRG-HN005 De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer. TM: G. Facio

Lung
2L-15-1 Biospecimen Bank & Biomrk/Lung Ca B. Desai
2L-17-1 Liquid Biopsy Research Project. A. Mejia

CTSU-A151216 ALCHEMIST- TM: G. Facio

Small Cell Lung
NRG-LU005 Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab (MPDL3280A) in LS-SCLC. TM: G. Facio

Non-Small Cell Lung
2N-13-6 Ph II Azacitidine +Entinostat NSCLC. TM: G. Facio
2N-17-2 (SUSPENDED) Ph3 Atezolizumab or Placebo + Platinum based Chemotherapy in NSCLC. TM: G. Facio / Massopust (NB)
2N-17-3 ([COHORT 2 CLOSED]) Ph2 Pozotinib in NSCLC with EGFR or HER2 Exon 20. TM: G. Facio

CTSU-A081105 (Erlotinib/ Placebo/EGFR Mutant NSCLC TM: G. Facio

CTSU-E4512 Ph3 Crizo vs Plac NSCLC. TM: G. Facio

Melanoma
10M-18-2 Ph/I dabrafenib, trametinib, & nivoltaxol in BRAF mutant melanoma. TM: C. Ketchens / K. Massopust (NB)
10M-19-2 Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-mutant Melanoma Brain Metastasis (POLARIS). TM: C. Ketchens
10M-19-3 A Study to Assess Safety and Efficacy of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-PD-1 Treatment. TM: C. Ketchens

CTSU-EA6174 Ph3 comparing MK-3475 (Pembrolizumab) to SOC in Merkel Cell Carcinoma. TM: C. Ketchens
SWOG-S1512 PHII PD-1 Blockade+MK-3475/Unresectable DM: TM: C. Ketchens
SWOG-S1607 (SUSPENDED) Ph2 Talimogene Laherparepvec + MK-3475 in Adv Melanoma PD on Anti-PD1/L1 Rx. TM: C. Ketchens
SWOG-S1801 Ph2 adj vs neoadj MK-3475 for clinically detectable stage III-IV melanoma. TM: C. Ketchens

Skin
CTSU-A091802 Ph2 RandAvelumab+ Cetuximab vs Avelumab in cSCC. TM: C. Ketchens

14SK-19-1 A PD-1 Checkpoint Inhibitor (Cemiplimab) for High-Risk Localized, Locally Recurrent, or Regionally Advanced Skin Cancer. TM: C. Ketchens / Andres (Hoag)

14SK-19-2 Ph1Intralesional Immunotherapy IFx-Hu2.0 Vaccine in Merkel Cell or CSCCarcinoma. TM: X. Menendez (NB)

Multiple Sites or Special Studies
05-04-7 USC Tumor &Tissue Banking. TM: G. Facio
05-11-5 Circulating Tumor Cell Collection. TM: C. Ketchens
05-12-3 (SUSPENDED) 11/17/18F-FMAU Imaging in Ca Pts. TM: B. Desai
05-12-4 (SUSPENDED) Cancer Genetics Registry. TM: C. Ketchens
05-15-12 Improving Patient Access to Ca Clin Trials (IMPACT Study). E. Nieves / A. Mejia
05-15-12 Norris ORIEN Total Cancer Care. Church
05-17-8 PhII-159 Talimogene laherparepvec followed Talimogene laherparepvec + Nivoltaxol. TM: C. Ketchens
05-18-5 Improving Patient Access to Ca Clin Trials (IMPACT Study). E. Nieves / A. Mejia
05-18-6 Precision Performance Status Assessment in Early Phase Clinical Trials. A. Mejia

05-19-2 (SUSPENDED) Vopratelimab and a CTLA-4 Inhibitor in Patients With HPV 16+ Confirmed Cancers. TM: C. Ketchens

05-19-6 A Study of TheraT® Vector(s) Expressing HPV 16+ in Patients With HPV 16+ Confirmed Cancers. TM: G. Facio